Rachel McMinn, Neurogene CEO
After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic
When former analyst Rachel McMinn started Neurogene from her apartment around three years ago, she would joke that they’d get office space as soon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
